Trials / Completed
CompletedNCT00546819
ZOSTAVAX™ in Patients on Chronic/Maintenance Corticosteroids (V211-017) (COMPLETED)
A Phase IIb Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Zoster Vaccine Live (Oka/Merck) in Patients on Chronic/Maintenance Corticosteroids
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 309 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study was to assess the safety, tolerability, and immunogenicity of ZOSTAVAX™ in patients receiving chronic/maintenance corticosteroids.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Zoster Vaccine, Live | A single dose of 0.65 ml Zoster Vaccine, Live, injected subcutaneously on Day 1 |
| BIOLOGICAL | Comparator: Placebo | A single dose of 0.65 ml Placebo to ZOSTAVAX™ injected subcutaneously on Day 1. |
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2010-08-01
- Completion
- 2010-08-01
- First posted
- 2007-10-19
- Last updated
- 2017-04-12
- Results posted
- 2011-08-15
Source: ClinicalTrials.gov record NCT00546819. Inclusion in this directory is not an endorsement.